Syra Health (SYRA) COO/CFO/Director Priya Receives Equity Awards

What Happened

• Priya Prasad, Syra Health’s COO, CFO and a director, was granted three equity awards on August 31, 2026 totaling 173,392 derivative shares (86,696 + 60,687 + 26,009). Each grant was reported as acquired at $0.00, indicating awards/grants (not open-market purchases or cash transactions). These are derivative awards (performance stock units, stock options and restricted stock units) that vest over time rather than immediately tradable shares.

Key Details

• Transaction date: August 31, 2026. Amended Form 4 filed September 28, 2026.
• Grant amounts: 86,696; 60,687; and 26,009 — total 173,392 shares (all reported as $0.00 per share; transaction code A = award/grant).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes (vesting terms):
  • F1: 20% of Performance Stock Units vest each year after grant, subject to certain company financial metrics.
  • F2: 20% of the options vest on each Dec 31 of 2026–2030.
  • F3: 20% of the restricted stock units vest on each Dec 31 of 2026–2030.
• Filing status: This is an amended Form 4 filed almost a month after the grant date; that is later than the usual two-business-day Form 4 reporting window.

Context

• These awards are derivative grants with multi-year vesting and (for at least one award) performance conditions — they do not represent immediate purchases of freely tradable shares. Such grants are common in executive compensation and are not, by themselves, a direct market buy or sell signal. Investors who track insider activity should watch future vesting, any exercises or subsequent sales, and check the full amended filing for additional ownership details.